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INTRODUCTION
Periodontitis is a highly prevalent
chronic inflammatory disease defined by
irreversible destruction of the hard and
soft tissues surrounding the teeth. Porphy-
romonas gingivalis, a causative factor for
periodontitis, is a black-pigmented, asac-
charolytic, anaerobic, gram-negative bac-
terium that produces a wide array of vir-
ulence factors and also is associated with
several systemic sequelae to periodonti-
tis. Lipopolysaccharide (LPS) and various
other microbe-associated molecular pat-
terns (MAMPs) of P. gingivalis initiate an
innate response primarily through en-
gagement of TLR-2 and -4 (1). Therefore,
considerable efforts have been made to
delineate intracellular signaling pathways
induced upon P. gingivalis–TLR interac-
tion to establish novel therapeutic targets
for periodontitis (1–4).
GSK3β is a constitutively active serine-
threonine kinase that plays a vital role in
directing the immune response following
TLR stimulation (5). Essentially, GSK3β is
known to be a key mediator of proin-
flammatory cytokine production during
bacterial infections and, subsequently, in-
hibition of GSK3β leads to an innate hy-
poreactivity to oral, and other, pathogens
(6). The specific mechanisms that drive
this suppression of the inflammatory re-
sponse are not completely understood
but are, nevertheless, highly complex. For
example, we have shown that GSK3β
controls the major immune modulating
molecule, IFN-β production in LPS
(TLR4)-stimulated human macrophages
via a c-Jun and activating transcription
factor (ATF)-2-dependent mechanism (7).
GSK3β also negatively regulates produc-
tion of the endogenous IL-1β antagonist,
IL-1R, via its ability to regulate the
 mitogen-activated protein kinase (MAPK)
extracellular-signal-regulated kinase
(ERK)1/2 in LPS-stimulated innate cells
by a mechanism that involves modula-
tion of the level of inhibitory residue
ser71 on Rac1 which, subsequently, con-
trols the ability of Rac1 to activate p21-ac-
tivated protein kinase (8). Of particular
interest is our recent identification of
IFN-β as a novel antiinflammatory thera-
peutic target that stimulates innate pro-
duction of IL-10 through activation of the
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Janus kinase 1 (JAK1)/phosphatidylinosi-
tol 3 kinase (PI3K)/protein kinase B1
(Akt1)/GSK3β signaling cascade (9). An-
toniv and Ivashikiv have shown that the
PI3K/Akt/GSK3 signaling axis controls
the activation of specific IL-10 inducible
genes in TLR-stimulated macrophages
(10). We also have shown that p85S6K-as-
sociated GSK3β is a kinase target for
mammalian target of rapamycin complex
1 (mTORC1), allowing control (inactiva-
tion) of GSK3β activity and, thus,
 regulation of the pro- versus antiinflam-
matory cytokine balance in TLR-4 stimu-
lated innate cells (11). Inhibitors of GSK3
also suppress signal transducer and acti-
vator of transcription (STAT)3 and STAT5
activation, providing a further mecha-
nism of differential inflammatory re-
sponse regulation (12). Stimulation of
 innate α7 nicotinic acetylcholine
(α7nAChR) receptors results in the con-
vergence of the cholinergic and GSK3β
antiinflammatory pathways (13). Thus,
α7nAChR has been determined to be a
potent, endogenous amplifier of GSK3β
antiinflammatory events (enhancement
of IL-10 and inhibition of NF-κB con-
trolled proinflammatory cytokines) in
TLR4- and whole P. gingivalis–stimulated
innate cells (13).
As the potential importance of GSK3β
in regulating periodontal inflammation
has been clearly established in vitro, as
recently reviewed (6) and as summarized
in Figure 1, we hypothesized that the cell
permeable GSK3-specific inhibitor,
SB216763, would protect against alveolar
bone loss induced by the key periodontal
pathogen, P. gingivalis. We set out to test




B6129SF2/J mice were purchased from
Jackson Laboratories (Bar Harbor, ME,
USA). Porphyromonas gingivalis ATCC
33277 was obtained from the American
Type Culture Collection (Manassas, VA,
USA). Trypticase soy broth (TSB) came
from BD (Franklin Lakes, NJ, USA). TNF
enzyme-linked immunosorbent assays
(ELISAs) were purchased from eBio-
science (San Diego, CA, USA). SB216763
was purchased from Tocris Bioscience/
R&D Systems (Minneapolis, MN, USA).
Sulfamethoxazole, trimethoprim, car-
boxymethylcellulose, dimethyl sulfoxide
(DMSO) and para formaldehyde came
from Sigma-Aldrich (St. Louis, MO,
USA). Fluorescein isothiocyanate (FITC)-
conjugated anti-mouse Ly6G (RB6-8C5)
and anti-human/mouse IL-17A antibod-
ies came from LifeSpan Biosciences (Seat-
tle, WA, USA) and Santa Cruz Biotech
(Santa Cruz, CA, USA), respectively.
Alexa Fluor 594–conjugated goat anti-
rabbit IgG was purchased from Molecu-
lar Probes/Life Technologies (Grand Is-
land, NY, USA). Immunocal solution was
bought from Decal Chemical Corpora-
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Figure 1. Rationale for targeting GSK3 to prevent TLR-induced alveolar bone loss. There is
a large body of existing, predominantly in vitro evidence, that, together, provide strong ra-
tionale for examining GSK3 as a potential therapeutic target for periodontal diseases. This
figure summarizes the key data. GSK3 is a constitutively active serine-threonine kinase
that, upon TLR engagement by P. gingivalis, acts as a downstream effector molecule in
the PI3K pathway that augments the production of proinflammatory cytokines including
TNF, IL-6, IL-12 and IL-1β. Such cytokines are known to promote osteoclastogenesis and
promote alveolar bone loss. Pharmacological inhibition of GSK3 suppresses the bacterial-
induced production of multiple proinflammatory cytokines while concurrently augment-
ing production of the antiinflammatory cytokine, IL-10. This occurs through a mechanism
that leads to a shift in the balance of nuclear NF-κB (p65)- and CREB-driven transcription
events. Further details are provided in the recent review by Wang et al. (6). Such alter-
ations to the pro- and antiinflammatory cytokine balance would be expected to sup-
press the progression of periodontitis. Therefore, it is hypothesized that the GSK3 inhibitor,
SB216763, will protect susceptible mice from P. gingivalis–mediated alveolar bone loss.
Those parts of the pathway that are relevant in vivo remain to be clarified. This report,
which confirms that pharmacological inhibition of GSK3b suppresses pathogen-induced
periodontal inflammation and alveolar bone loss, represents a first step in this process.
tion (Tallman, NY, USA) and OCT com-
pound came from Fisher Scientific (Pitts-
burgh, PA, USA). Procarta Mouse Cy-
tokine Assay Kits were purchased from
Affymetrix (Santa Clara, CA, USA).
Growth of Porphyromonas gingivalis
P. gingivalis ATCC 33277 cells were
grown in TSB under anaerobic condi-
tions (85% N2, 10% H2, 5% CO2) at 37°C.
SB216763 (0 to 125 μm) did not influence
the growth of P. gingivalis in planktonic
cultures compared with untreated and
solvent controls (data not shown).
P. gingivalis–Induced Bone Loss
Model
An established P. gingivalis–induced
periodontal bone loss model (14) was
utilized. The oral microflora was sup-
pressed in 10- to 12-wk-old B6129SF2/J
mice by sulfamethoxazole (800 μg mL-1)
and trimethoprim (400 μg mL–1) pro-
vided ad libitum in water for 10 d. The
mice then received pure drinking water
for 3 d. Alveolar bone loss was induced
by oral infection with 1 × 109 CFU of live
P. gingivalis suspended in 100 μL of
phosphate-buffered saline with 2% car-
boxymethylcellulose directly by gavage.
Infections were performed five times at
2-d intervals. The experimental group
was also administered intraperitoneally
(IP) SB216763 (10 mg/kg) 1 d prior to in-
fection and every other day thereafter
until euthanization. Sham-infected and
vehicle controls also were established.
The mice were euthanized with CO2 and
cervical dislocation 42 d after the final in-
fection. Alveolar bone loss was measured
in millimeters at 14 predetermined
points on the maxillary molars of de-
fleshed maxillae as the distance from the
cementoenamel junction (CEJ) to the
alveolar bone crest (ABC). Bone loss was
visualized by methylene blue/eosin
staining and quantified using a Nikon
SMX 800 dissecting microscope (40×;
Nikon Instruments Inc., Melville, NY,
USA) fitted with a Boeckeler VIA-170K
video image marker measurement sys-
tem (Boeckeler Instruments Inc, Tucson,
AZ, USA). The results were expressed as
the mean and standard deviation. The
experimental protocol was reviewed and
approved by the Institutional Animal
Care and Use Committee, University of
Louisville (IACUC # 10045).
Evaluation of Periodontal
Inflammation
Neutrophil infiltration and IL-17 ex-
pression were monitored by immunohis-
tochemistry, as described recently by
Eskan et al. (15). Jawbones were fixed in
4% paraformaldehyde, decalcified in im-
munocal solution for 15 d and embedded
in OCT compound. 7- to 8-μm mesiodis-
tal sections were stained with FITC-con-
jugated anti-mouse Ly6G, a neutrophil
marker, or with anti-human/ mouse IL-17
antibodies visualized using Alexa Fluor
594–conjugated goat anti-rabbit IgG. The
specificity of staining was confirmed by
using an FITC- conjugated isotype control
or normal rabbit IgG followed by Alexa
Fluor 594–goat anti-rabbit IgG. Images
were captured using a laser-scanning
confocal microscope (Olympus FV1000;
Olympus America Inc., Center Valley,
PA, USA). Quantitative data are pre-
sented as mean comparative fluorescence
intensity ± standard deviation. Quantifi-
cation was performed using ImageJ soft-
ware v1.46 [NIH, Bethesda, MD, USA;
http://rsb.info.nih.gov/ij/].
Evaluation of Systemic Inflammation
Systemic cytokine concentrations
(IL-12 p40, IL-1β and IL-6) were deter-
mined in mouse serum in duplicate with
the Procarta Mouse Cytokine Assay Kit
and Luminex 100, according to the man-
ufacturer’s instructions (eBioscience).
TNF concentrations were determined by
ELISA, according to the manufacturer’s
instructions (eBioscience).
Statistical Approaches
Statistical significance between groups
was evaluated by analysis of variance
(ANOVA) and Tukey multiple-comparison
test using the InStat program (GraphPad
Software, San Diego, CA, USA). Differ-
ences between groups were considered sig-
nificant at the level of p < 0.05.
RESULTS
Inhibition of GSK3β Abrogates
P. gingivalis–Induced Bone Loss
Typical photographs of pathogen-
 induced bone loss in methylene blue-
stained murine maxillae are presented in
Figure 2. As expected, alveolar bone loss
was readily induced in B6129SF2/J mice
by P. gingivalis compared with sham-
 infected controls. Such hard tissue de-
struction appeared to be completely abro-
gated by the systemic administration of
the GSK3 inhibitor, SB216763. The seven
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Figure 2. Visualization of P. gingivalis–
 induced bone loss. 8- to 12-wk-old
B6129SF2/J mice were divided randomly
into three control groups and two experi-
mental groups (n = 5 per group). The con-
trol groups were treated with cellulose
(sham infected), 0.02% DMSO, or SB216763
(10 mg/kg) respectively. The experimental
groups were infected orally with P. gingi-
valis 33277 with or without pretreatment
with the GSK3 inhibitor, SB216763
(10 mg/kg). Alveolar bone loss was visual-
ized by methylene blue/eosin staining 6
wks later. Typical maxillae from (A) sham-
infected, (B) P. gingivalis–infected, and (C)
SB216763-treated, P. gingivalis–infected
mice are presented.
predetermined points on the buccal sur-
face of the maxillary molars used to as-
sess alveolar bone loss are highlighted in
Figure 2A. Bone loss also was measured
on the equivalent points on the opposing
buccal surface. As shown in Figure 3, P.
gingivalis–induced bone loss was signifi-
cantly greater than each of the three con-
trol groups: sham infected (cellulose) (p <
0.01); DMSO (p < 0.05); and SB216763
only (p < 0.01). Critically, pharmacological
inhibition of GSK3 reduced pathogen-in-
duced bone destruction to control levels.
Inhibition of GSK3β Reduces
P. gingivalis–Induced Periodontal
Inflammation
Neutrophil infiltration into gingival tis-
sues, visualized as Ly6G-positive cells,
was reduced in mice inoculated with
P. gingivalis and treated with SB216763,
compared with the P. gingivalis–induced
bone loss group (Figure 4B). Similarly, the
proinflammatory cytokine IL-17 was also
reduced upon GSK3 inhibition (Figure
4C). Double immunofluorescence staining
suggested that neutrophils were a major,
but not sole, source of IL-17 in the mice
that developed bone loss (Figure 4D).
Inhibition of GSK3β Reduces
P. gingivalis–Induced Systemic
Inflammation
As shown in Figure 5, oral inoculation
of mice with P. gingivalis led to systemic
inflammation, quantified as the serum
concentration of proinflammatory cy-
tokines, 42 d after the final bacterial in-
fection. This P. gingivalis–induced circu-
lating burden of IL-12 p40, TNF, IL-1β
and IL-6 was reduced to levels close to
those seen in uninoculated controls on
SB216763 treatment.
DISCUSSION
Regulation of TLR signaling is critical
in the determination of the qualitative
and quantitative ferocity of the inflamma-
tory response to microbial insult (5). We
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Figure 3. Quantification of P. gingivalis–
 induced bone loss. The distance from the
cementoenamel junction (CEJ) to the
alveolar bone crest (ABC) was measured 
6 wks after infection at 14 predetermined
maxillary buccal sites in 8- to 12-wk-old
B6129SF2/J mice divided into three control
(cellulose, DMSO, or SB216763 treated) and
two experimental (P. gingivalis–infected;
and SB216763-treated, P. gingivalis–infected
mice) groups. Data are presented as mean
distance CEJ-ABC in mm ± s.d. n = 5 mice
per group. *p < 0.05 compared with 
P. gingivalis–treated group. **p < 0.01 com-
pared with P. gingivalis–treated group.
Figure 4. Quantification of maxillary neutrophil infiltration and IL-17 expression. Typical (A)
Hematoxylin and eosin (H and E)–stained and (B) confocal microscopy images of Ly6G-
postive neutrophil infiltration, (C) IL-17 expression and (D) IL-17 expressing Ly6G-postive
cells in periodontal tissues are presented. The mean comparative fluorescence intensity
for (E) neutrophils and (F) IL-17 also are presented. Error bars represent the standard devi-
ation. ***p < 0.001 compared with P. gingivalis bone loss group. Pg, P. gingivalis infected;
Pg + SB216763, SB216763 treated and P. gingivalis infected. Scale bars, 50 μm.
have established previously that the en-
gagement of the α7nAChR cholinergic
antiinflammatory pathway amplifies the
PI3K pathway in a GSK3-dependent
manner (13). GSK3β inhibition differen-
tially affects the nuclear amounts of tran-
scription factors NF-κB subunit p65 and
CREB interacting with the coactivator cal-
cium-binding protein (CBP) (5). Conse-
quently, TLR-initiated proinflammatory
cytokine production (IL-1β, IL-8, TNF, IL-
12) in response to P. gingivalis is potently
suppressed, concurrent with the upregu-
lation of the antiinflammatory cytokine,
IL-10 (13). This represents a powerful an-
tiinflammatory mechanism, at least in
vitro. Endogenously, GSK3β is inactivated
by phosphorylation of the Ser9 residue
(16). GSK3β inhibition also can be
achieved pharmacologically, for example,
by SB216763. Recently, it has been estab-
lished that Wortmannin, which inhibits
PI3K and, thus, reduces GSK3β phospho-
rylation (preventing the inactivation of
this constitutively active kinase), aug-
ments liver damage in a murine hepatic
ischemia-reperfusion model (17). Simi-
larly, GSK3β inhibition has been shown
to reduce chronic intestinal inflammation
significantly in a dextran sodium sulfate-
induced colitis model (18). Herein, we
have established that these phenomena
may be active in the oral cavity in vivo, as
inhibition of GSK with SB216763 reduces
periodontal inflammation and abrogates
pathogen-induced periodontitis in mice.
Murine alveolar bone loss models have
been used to examine the importance of
multiple innate cell surface receptors and
intracellular signaling molecules, includ-
ing TLR-2, complement component 3a
receptor (C3aR), complement component
5a receptor (C5aR), C-C chemokine re-
ceptor type 2 (CCR2), receptor activator
of nuclear factor-κB ligand (RANK-L)
and MAPK–MAP kinase phosphatase 1
(MPK1) (19–21) in perio dontitis. Whereas
significant roles in perio dontal bone loss
were found for several of these inflam-
matory modulators, the potency of GSK3
inhibition in abrogating P. gingivalis–in-
duced periodontal disease progression in
this model is striking. Considering the
complexity of periodontal disease etiol-
ogy, the efficacy of such a single thera-
peutic agent is perhaps surprising. On
the other hand, validation of the current
findings will confirm the critical impor-
tance of GSK3 as a central regulator of
the inflammatory response to microbial
infections.
P. gingivalis persistence may not be
clinically significant, because the ulti-
mate goal is to prevent and/or treat
 periodontal disease, thus, many studies
testing potential antiinflammatory ther-
apeutics for the inhibition of bacterial-
 induced alveolar bone loss have not as-
sessed the fate of the inoculum (22–25).
Yuan et al. showed that immune modu-
lation via RANKL antagonism sup-
pressed P. gingivalis–induced inflamma-
tion and bone loss in vivo, but did not
influence pathogen colonization (20).
We did not quantify infection with P.
gingivalis. However, all animals were
dosed equally with this pathogen and
inflammatory indices were measured
chronically after  inoculation. Further-
more, inhibition of GSK3β is known to
suppress the immune response, as we
have confirmed in our model herein.
Thus, we would expect any remaining
P. gingivalis infection to be higher in the
SB216763-treated group. Yet, the inflam-
matory indices and bone loss are lower
in this experimental group. Neutrophils
are protective in so much as they con-
trol the pathogenic population, attack-
ing bacteria in the gingival crevice, ex-
ternal to the periodontal soft and hard
tissues, and they also scavenge cellular
debris. As we have recently reviewed
(26), however, there is a clear associa-
tion between neutrophil infiltration into
periodontal tissues and the severity and
progression of inflammatory periodon-
tal diseases (27–31). The importance of
IL-17 in the promotion of osteoclastoge-
nesis, bone loss and periodontitis is
now recognized (15,32–36), while P.
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Figure 5. Systemic cytokine response to P. gingivalis infection and GSK3 inhibition. Systemic
cytokine concentrations were determined in mouse serum collected at euthanization,
42 d from the last infection, using Luminex technology (IL-12 p40, IL-1β and IL-6) or ELISA
(TNF). Assays were performed in duplicate with n = 5 mice per group. Data are presented
as mean cytokine concentration in pg/mL ± s.d. ***p < 0.001 compared with the P. gingi-
valis bone loss group.
gingivalis has been shown to induce in-
nate cell IL-17 production and promote
Th17 polarization (37,38). We establish
that SB216763 suppresses the infiltra-
tion of neutrophils to the periodontal
tissues of P. gingivalis–loaded animals.
Interestingly, local expression of IL-17
also is suppressed upon GSK3β inhibi-
tion. IL-17, recently recognized as a key
mediator of inflammatory alveolar 
bone loss, promotes neutrophil
hematopoiesis and attracts and acti-
vates neutro phils (15,39,40).
Periodontitis occurs in approximately
50% of the population, resulting in sig-
nificant debilitation for about half of
these persons (41,42), and represents an
enormous economic burden that con-
sumes >$14 billion per annum in the
United States alone (43). Furthermore,
 increasing evidence suggests that peri-
odontitis is associated with increased
risk of vascular diseases (including coro-
nary artery disease and stroke), diabetes
mellitus, lung diseases (chronic obstruc-
tive pulmonary disease [COPD] and
pneumonia), and preterm delivery
(44,45). Thus, the potential significance
and impact of controlling or reducing
pathogen-induced periodontal diseases
is enormous. In keeping with the concept
of increased systemic inflammation dur-
ing periodontitis, we have shown that
P. gingivalis–loaded mice exhibit both
alveolar bone loss and significantly in-
creased systemic concentrations of TNF
and IL-12/IL-23 p40, compared with
control mice. These same cytokines are
known to be suppressed by GSK3β inhi-
bition in vitro and in other animal mod-
els, including a murine endotoxic shock
model (5). We show, for the first time,
that SB216763 reduces not only peri-
odontal inflammation, but also the circu-
lating TNF and IL-12/IL-23 p40 burden.
Thus, it is possible that GSK3β inhibition
may protect against the chronic, systemic
sequelae associated with periodontal dis-
eases. It is interesting that both IL-6 and
IL-23 are known to induce Th17 cell dif-
ferentiation (46). The possibility of sys-
temic sequelae due to persistent P. gingi-
valis will need to be tested in future
studies, although the fact that circulating
cytokines are significantly reduced in 
P. gingivalis–inoculated, GSK3β-inhibited
animals is a promising sign. Potential
side effects of SB216763 will also need to
be considered carefully.
CONCLUSION
To the best of our knowledge, this is
the first in vivo report of GSK3 as a novel,
efficacious therapeutic preventing peri-
odontal disease progression in a suscep-
tible host. It is hoped that these data can
serve as a basis for the rational design of
intervention therapeutic strategies for
manipulating the innate immune re-
sponse in the periodontium. Future stud-
ies will be required to confirm and fur-
ther elucidate the mechanisms by which
SB216763 and other GSK3 inhibitors
block periodontal disease progression in
response to pathogenic insult.
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